Considering all the treatments they received for rheumatic disease, 11 (78.6%) patients were treated with steroids, 8 (57.1%) patients with hydroxychloroquine (HCQ), 4 (28.6%) patients with MTX, 4 (28.6%) patients with sulfasalazine (SLZ), 2 (14.3%) patients with leflunomide (LEF), and 1 (7.1%) patient with anti-TNF (etanercept). This evidence concerns the gene TNF and rheumatic disorder.